PE20170333A1 - Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados - Google Patents
Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionadosInfo
- Publication number
- PE20170333A1 PE20170333A1 PE2016001893A PE2016001893A PE20170333A1 PE 20170333 A1 PE20170333 A1 PE 20170333A1 PE 2016001893 A PE2016001893 A PE 2016001893A PE 2016001893 A PE2016001893 A PE 2016001893A PE 20170333 A1 PE20170333 A1 PE 20170333A1
- Authority
- PE
- Peru
- Prior art keywords
- dyslipidemia
- obesity
- diabetes
- treatment
- related disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invencion proporciona derivados de isoindolinona de formula I, en donde: X es N, C-R1a; A es CR31R33, NR31, CR31R33-NR31, CR31=N; R30 es H, (CR11R12)n-R32; R1b y R1c son H, F, Cl, Br, alquilo C1-C6, CN; R2a, R2b y R2c son H, F, Cl, Br, entre otras opciones; Y es N, CH; Z es un enlace, O, CR5R5, NR6, C=O, S, SO, SO2; R3 es un enlace, (CR7R7)p; y R4 es F, Cl, SF5, alquilo C1-C6, entre otras opciones. Estos compuestos son moduladores de GPR119 y son utiles para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados. Tambien se incluyen composiciones que comprenden estos compuestos. Entre los compuestos preferidos tenemos: 2-[6-[(3R)-3-[[6-(ciclopropilmetoxi)-3-piridil]oxi]-2-oxo-pirrolidin-1-il]-4-fluoro-1-oxo-isoindolin-2-il]acetato de terc-butilo; Acido 2-[6-[(3R)-3-[[6-(ciclopropilmetoxi)-3-piridil]oxi]-2-oxo-pirrolidin-1-il]-4-fluoro-1-oxo-isoindolin-2-il]propanoico, entre otros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14305496 | 2014-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20170333A1 true PE20170333A1 (es) | 2017-04-21 |
Family
ID=50513860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2016001893A PE20170333A1 (es) | 2014-04-04 | 2015-04-02 | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
Country Status (20)
Country | Link |
---|---|
US (1) | US9908868B2 (es) |
EP (1) | EP3126350B1 (es) |
JP (1) | JP2017509678A (es) |
KR (1) | KR20160132415A (es) |
CN (1) | CN106164068A (es) |
AR (1) | AR099937A1 (es) |
AU (1) | AU2015239022A1 (es) |
CA (1) | CA2943864A1 (es) |
CL (1) | CL2016002498A1 (es) |
DO (1) | DOP2016000226A (es) |
EA (1) | EA201692007A1 (es) |
EC (1) | ECSP16078782A (es) |
IL (1) | IL248130A0 (es) |
MA (1) | MA39359A1 (es) |
MX (1) | MX2016013037A (es) |
PE (1) | PE20170333A1 (es) |
PH (1) | PH12016501724A1 (es) |
SG (1) | SG11201607247TA (es) |
TW (1) | TW201623286A (es) |
WO (1) | WO2015150565A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201623286A (zh) | 2014-04-04 | 2016-07-01 | 賽諾菲公司 | 作為gpr119調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物 |
ES2776359T3 (es) | 2014-04-04 | 2020-07-30 | H Lundbeck As | Quinazolin-thf-aminas halogenadas como inhibidores de PDE1 |
CN105399744B (zh) * | 2015-12-17 | 2017-07-18 | 黄燕鸽 | 一种奥格列汀的合成方法 |
JP7086942B2 (ja) * | 2016-09-12 | 2022-06-20 | インテグラル ヘルス, インコーポレイテッド | Gpr120モジュレーターとして有用な単環式化合物 |
JP7065081B2 (ja) * | 2016-09-12 | 2022-05-11 | インテグラル ヘルス, インコーポレイテッド | Gpr120モジュレーターとして有用な二環式化合物 |
WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2018153849A1 (en) | 2017-02-21 | 2018-08-30 | Sanofi | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
WO2018170067A1 (en) * | 2017-03-14 | 2018-09-20 | Dana-Farber Cancer Institute, Inc. | Small molecule sensitization of bax activation for induction of cell death |
IT201700039562A1 (it) * | 2017-04-10 | 2018-10-10 | Univ Pisa | Derivati isoindolinici quali attivatori di ampk |
TWI714231B (zh) * | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
KR102289381B1 (ko) * | 2020-03-17 | 2021-08-17 | 주식회사 대웅테라퓨틱스 | 당뇨치료제 및 고지혈증 치료제를 포함하는 약학적 조성물 |
BR112022023359A2 (pt) | 2020-05-19 | 2023-04-18 | Kallyope Inc | Ativadores de ampk |
EP4172162A1 (en) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Ampk activators |
CN117164597B (zh) * | 2023-11-02 | 2024-02-09 | 深圳创元生物医药科技有限公司 | 一种smtp-0合成方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0410561A (pt) * | 2003-06-18 | 2006-06-20 | Pfizer Prod Inc | lactamas de piperazinileteroarilóxi-n-arill e de piperazinilarilóxi |
TWI389897B (zh) * | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
MX2012013465A (es) | 2010-05-17 | 2013-12-02 | Array Biopharma Inc | Lactamas sustituidas con piperidinilo como moduladores de gpr119. |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
SG188985A1 (en) | 2010-09-17 | 2013-05-31 | Array Biopharma Inc | Piperidinyl-substituted lactams as gpr119 modulators |
AU2012336157A1 (en) | 2011-11-11 | 2014-05-29 | Glaxosmithkline Llc | Treatment of blood lipid abnormalities and other conditions |
TW201623286A (zh) | 2014-04-04 | 2016-07-01 | 賽諾菲公司 | 作為gpr119調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物 |
-
2015
- 2015-04-01 TW TW104110614A patent/TW201623286A/zh unknown
- 2015-04-01 AR ARP150100990A patent/AR099937A1/es unknown
- 2015-04-02 JP JP2016560724A patent/JP2017509678A/ja not_active Abandoned
- 2015-04-02 CA CA2943864A patent/CA2943864A1/en not_active Abandoned
- 2015-04-02 EA EA201692007A patent/EA201692007A1/ru unknown
- 2015-04-02 MX MX2016013037A patent/MX2016013037A/es unknown
- 2015-04-02 SG SG11201607247TA patent/SG11201607247TA/en unknown
- 2015-04-02 AU AU2015239022A patent/AU2015239022A1/en not_active Abandoned
- 2015-04-02 EP EP15714502.0A patent/EP3126350B1/en active Active
- 2015-04-02 KR KR1020167026832A patent/KR20160132415A/ko unknown
- 2015-04-02 CN CN201580017439.8A patent/CN106164068A/zh active Pending
- 2015-04-02 MA MA39359A patent/MA39359A1/fr unknown
- 2015-04-02 PE PE2016001893A patent/PE20170333A1/es not_active Application Discontinuation
- 2015-04-02 WO PCT/EP2015/057415 patent/WO2015150565A1/en active Application Filing
-
2016
- 2016-08-29 DO DO2016000226A patent/DOP2016000226A/es unknown
- 2016-09-01 PH PH12016501724A patent/PH12016501724A1/en unknown
- 2016-09-29 IL IL248130A patent/IL248130A0/en unknown
- 2016-09-30 CL CL2016002498A patent/CL2016002498A1/es unknown
- 2016-10-03 US US15/284,334 patent/US9908868B2/en not_active Expired - Fee Related
- 2016-10-04 EC ECIEPI201678782A patent/ECSP16078782A/es unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2016000226A (es) | 2016-10-31 |
MX2016013037A (es) | 2017-01-09 |
ECSP16078782A (es) | 2017-02-24 |
TW201623286A (zh) | 2016-07-01 |
SG11201607247TA (en) | 2016-09-29 |
US9908868B2 (en) | 2018-03-06 |
CA2943864A1 (en) | 2015-10-08 |
PH12016501724A1 (en) | 2016-10-03 |
US20170022182A1 (en) | 2017-01-26 |
EA201692007A1 (ru) | 2017-02-28 |
IL248130A0 (en) | 2016-11-30 |
EP3126350A1 (en) | 2017-02-08 |
AU2015239022A1 (en) | 2016-10-13 |
AR099937A1 (es) | 2016-08-31 |
KR20160132415A (ko) | 2016-11-18 |
CN106164068A (zh) | 2016-11-23 |
JP2017509678A (ja) | 2017-04-06 |
EP3126350B1 (en) | 2018-07-04 |
CL2016002498A1 (es) | 2017-07-21 |
MA39359A1 (fr) | 2017-09-29 |
WO2015150565A1 (en) | 2015-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20170333A1 (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
PE20131197A1 (es) | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen | |
PE20141726A1 (es) | Heterociclilaminas como inhibidores de pi 3k | |
PE20190511A1 (es) | Piridinas sustituidas con heteroarilo y metodos de uso | |
CO6361937A2 (es) | Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PE20181197A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
UY31878A (es) | Miméticos de glucocorticoides, métodos para su fabriciación, composiciones farmacéuticas y usos de los mismos | |
CO7400867A2 (es) | Modificador del sabor dulce | |
PE20170677A1 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret) | |
PE20181145A1 (es) | Compuestos de piridina | |
PE20090188A1 (es) | Compuestos heterociclicos como moduladores de la senda de hedgehog | |
UY39338A (es) | Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos | |
PE20141360A1 (es) | Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos. | |
PE20142339A1 (es) | Derivados macrociclicos para el tratamiento de enfermedades | |
PE20150339A1 (es) | Carboxamidas heterociclicas fungicidas | |
PE20180040A1 (es) | Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas | |
UY36101A (es) | Herbicidas de piridazinona | |
PE20151001A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
PE20161378A1 (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y transtornos relacionados | |
PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
PE20161552A1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
PE20160661A1 (es) | Compuesto de azapiridona y sus usos de los mismos | |
PE20150774A1 (es) | Aminoquinolinas como inhibidores de cinasa | |
AR073622A1 (es) | Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |